Clinical trials: Haematological Cancer
Hematological Malignancy
Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours
The trial is designed as an early exploratory single-centre, open, single-arm clinical trial. The trial is planned to evaluate the safety and efficacy of CAR-T for the treatment of relapsed refractory malignant haematological…
- Trial name
- NCT06238336
- Testing
- CAR-T cell therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanxi Bethune Hospital
Gammopathy, Monoclonal
Monoclonal Gammopathy With Clinical Significance in Patients With and Without Haematological Malignancies in Finistère Between 2012 and 2017 (GammaClinik)
Clinical symptoms associated with monoclonal gammapathy have been primarily studied in hematological malignancy and rarely in MGUS and hemopathy.
- Trial name
- GammaClinik (NCT06559579)
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Brest
Fatigue, Leukemia
Effects of Periodized and Autoregulated Resistance Training in Haematological Cancer Patients During the Treatent.
Several clinical trials have demonstrated the positive impact of physical functioning and fatigue in patients who received training programs during the myeloablative chemotherapy with stem cell transplantation.
- Conditions
- Fatigue, Leukemia, Lymphoma, Physical Disability
- Trial name
- NCT04406285
- Testing
- Standard protocol Leukemia, Periodic Resistance Training Program Leukemia, Standard protocol Lymphoma
- Where
- 2 sites in Brazil
- Volunteers
- 66 people
- Sponsor
- Federal University of Health Science of Porto Alegre
Haematological Malignancy, Acute Leukemia
Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation
Allogeneic haematopoietic stem cell transplantation (aHSCT) is the only curative treatment for many paediatric and young adult haematological pathologies (acute leukaemia, myelodysplastic syndromes haemoglobinopathies, bone…
- Conditions
- Haematological Malignancy, Acute Leukemia, Myelodysplastic Syndromes, Hemoglobinopathy in Children
- Trial name
- EVAADE (NCT05298930)
- Testing
- Physical activity program
- Where
- France
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Centre Leon Berard
Hematologic Malignancies, Thrombopenia
Interpretability of the Quantra® Viscoelastic Test in Patients With Haematological Malignancies With Profound Thrombocytopenia Below 50x10 G/L.
The goal of this single-center, non-controlled, non-randomized exploratory clinical trial is to evaluate the interpretability of viscoelastic tests (Quantra® and ROTEM® type) in relation to platelet levels measured in standard…
- Trial name
- VISCOTHEM-1 (NCT06455553)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Centre Hospitalier Annecy Genevois
Haematological Abnormality
The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients
To determine the effective functionality/potency of Jobelyn as an immunologic and haematologic booster in Breast cancer patients (start-off), thus improving the outlook and the quality of life of such patients generally
- Trial name
- NCT01936064
- Testing
- Jobelyn + Cyclophosphamide-Epirubicin6
- Where
- 2 sites in Nigeria
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Lagos State University
Hematologic Neoplasms
Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion
The overall objective of this study is to collect preliminary effectiveness and safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with hematological malignancies.
- Trial name
- NCT06685848
- Testing
- Hemanext ONE system, Conventional RBCs
- Where
- 2 sites in United States, Norway
- Volunteers
- 24 people
- Sponsor
- Hemanext
Haematological Malignancy, Colorectal Neoplasms
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other…
- Conditions
- Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms
- Trial name
- DETERMINE (NCT05786716)
- Testing
- Trastuzumab, Pertuzumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Adults, Hematological Malignancy
A Mixed Method to Study Adherence to Oral Anticancer Medications in a Multilingual and Multicultural Setting
Patients with haematologic malignancies are increasingly treated by Oral Anticancer Medications (OAMs), increasing the challenge of ensuring optimal adherence to treatment.
- Conditions
- Adults, Hematological Malignancy, Oral Antineoplastic Agents
- Trial name
- MADESIO (NCT04613765)
- Testing
- Measure adherence behaviors
- Where
- 2 sites in Belgium
- Volunteers
- 113 people
- Sponsor
- Jules Bordet Institute
Acute Myeloid Leukemia, Myelodysplastic Syndrome
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
This phase I trial studies the side effects and best dose of anti-cluster of differentiation (CD)47 monoclonal antibody Hu5F9-G4 in treating patients with haematological malignancies including acute myeloid leukemia that has…
- Trial name
- NCT02678338
- Testing
- Hu5F9-G4
- Where
- 5 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Myelodysplastic Syndromes, Leukemia Myeloid Acute
Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies
The elderly comprise the most prevalent population in oncology practice. The available evidence suggests that old patients are undertreated patients, mainly because of their advanced age, regardless of whether they are highly…
- Conditions
- Myelodysplastic Syndromes, Leukemia Myeloid Acute, Multiple Myeloma, Leuklemia, Lymphocytic, Chronic
- Trial name
- GAH (NCT02164071)
- Testing
- Geriatric Assessment of Health Status Scale administration
- Where
- 22 sites in Spain
- Volunteers
- 363 people
- Sponsor
- Celgene
Haematological Cancer
Adapted Boxing and Photography in Haematology: Body Image and Self-Esteem
Although the benefits of adapted physical activity (APA) are well documented in the scientific literature, few studies have specifically examined the impact of adapted boxing on body image and self-esteem in patients with…
- Trial name
- BOXITUDE (NCT07888959)
- Testing
- adapted boxing session
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)
The study will be an open label, single arm, phase I study intended to identify the safety and tolerability of "AML Cell Vaccine" given to eligible MDS RAEB-2 and AML patients who have achieved a best response of complete…
- Trial name
- NCT02493829
- Testing
- AML Cell Vaccine
- Volunteers
- 10 people
- Sponsor
- King's College London
Adapted Physical Activity, Hematological Malignancies
APA and Relaxation by Biofeedback in Patients With Haematological Malignancy Admitted in ICU
Adapted Physical Activity (APA) is accepted as an effective, recommended and beneficial supportive care for the health of people with cancer during the different phases of the disease.
- Conditions
- Adapted Physical Activity, Hematological Malignancies, Anxiety, Relaxation
- Trial name
- APAER_H (NCT05475600)
- Testing
- Classical APA group:, APA with Exergaming device, APA associated with biofeedback relaxation
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Leukemia
Natural Killer Cells Functions, Tumoral Escape to Immune System and Regulation of Natural Cytotoxixity Receptors in Haematological Malignancies
The NK cells participate in the innate immunity against infectious agents or transformed cells that are recognized as "no self" by the absent, weak or abnormal expression of human leukocyte antigen (HLA) class I molecules.
- Trial name
- NCT01915992
- Testing
- blood samples
- Where
- France
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Haematological Malignancies, Allogeneic Stem Cell Transplant
CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation
The investigators propose a nonrandomized, Phase I study to assess the safety of infusion of NK cells that will be selected from sibling donors and infused to patients with hematological malignancies early following allogeneic…
- Conditions
- Haematological Malignancies, Allogeneic Stem Cell Transplant, CD56+CD3- NK Cells
- Trial name
- NCT01336478
- Testing
- Infusion of donor derived ex-vivo selected NK cells to patients after transplant, Haematology / Blood chemistry sampling
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Imperial College London
Allogeneic Stem Cell Transplantation
Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH
The allogeneic hematopoietic stem cell marrow is the only curative treatment for many hematologic malignancies. However, many patients relapse in these situations to be therapeutic possibilities scarce and mixed.
- Trial name
- NCT01212796
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Solid Tumour, Malignant Haematological Tumour
Nivestim™ in Treatment of Malignant Diseases
The purpose of this study is to observe the tolerability, safety and efficacy of preventative treatment using Nivestim™ in patients receiving cytotoxic chemotherapy for cancer.
- Conditions
- Solid Tumour, Malignant Haematological Tumour, Primary or Secondary Prophylactic Treatment
- Trial name
- NCT01627990
- Where
- 48 sites in Germany
- Volunteers
- 386 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Solid Cancer, Haematological Malignancies
Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Patients Receiving Oral Treatment for Cancer or Malignant Haemopathy (ACCELER PLATFORM)
This is an open-label, single-centre, category 2 "Jardé Law" proof-of-concept study designed to demonstrate the feasibility of a decentralised care pathway for patients with cancer or haematological malignancies receiving oral…
- Trial name
- NCT06797037
- Testing
- Decentralised Pathway Coordinated by the Advanced Practice Nurse
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Institut Claudius Regaud
Hematological Infection
A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM)
MDR (multidrug resistant) gram-negative bacteria have emerged as an important cause of bloodstream infection in hospitalized patients, especially in immunocompromised hosts.
- Trial name
- DEHAM (NCT02966457)
- Testing
- Colistimethate Sodium
- Where
- Belarus
- Volunteers
- 62 people
- Sponsor
- Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology